36
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Prediction of Thorough QT study results using action potential simulations based on ion channel screens

      research-article
      a , * , b , c , d , e , a , f
      Journal of Pharmacological and Toxicological Methods
      Elsevier
      AP(D), action potential (duration), AZ, AstraZeneca, B&Q2, IonWorks Barracuda and second Quattro screening dataset, GLP, good laboratory practice, GSK, GlaxoSmithKline, IC50, concentration for 50% inhibition, ICaL, long-lasting-type calcium current, IKr, rapid delayed rectifier potassium current, IKs, slow delayed rectifier potassium current, INa, fast sodium current, Ito, transient outward potassium current, M&Q, manual hERG plus IonWorks Quattro screening dataset, pIC50, minus log10 of IC50, Q, IonWorks Quattro screening dataset, QT[c], QT interval of the electrocardiogram [corrected for heart rate], TQT, Thorough QT (or ECG) study, a human clinical trial, High-throughput, Compound screening, Thorough QT, Cardiac safety, Methods, Action potential, Mathematical model

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Detection of drug-induced pro-arrhythmic risk is a primary concern for pharmaceutical companies and regulators. Increased risk is linked to prolongation of the QT interval on the body surface ECG. Recent studies have shown that multiple ion channel interactions can be required to predict changes in ventricular repolarisation and therefore QT intervals. In this study we attempt to predict the result of the human clinical Thorough QT (TQT) study, using multiple ion channel screening which is available early in drug development.

          Methods

          Ion current reduction was measured, in the presence of marketed drugs which have had a TQT study, for channels encoded by hERG, CaV1.2, NaV1.5, KCNQ1/MinK, and Kv4.3/KChIP2.2. The screen was performed on two platforms — IonWorks Quattro (all 5 channels, 34 compounds), and IonWorks Barracuda (hERG & CaV1.2, 26 compounds). Concentration–effect curves were fitted to the resulting data, and used to calculate a percentage reduction in each current at a given concentration.

          Action potential simulations were then performed using the ten Tusscher and Panfilov (2006), Grandi et al. (2010) and O'Hara et al. (2011) human ventricular action potential models, pacing at 1 Hz and running to steady state, for a range of concentrations.

          Results

          We compared simulated action potential duration predictions with the QT prolongation observed in the TQT studies. At the estimated concentrations, simulations tended to underestimate any observed QT prolongation. When considering a wider range of concentrations, and conventional patch clamp rather than screening data for hERG, prolongation of ≥ 5 ms was predicted with up to 79% sensitivity and 100% specificity.

          Discussion

          This study provides a proof-of-principle for the prediction of human TQT study results using data available early in drug development. We highlight a number of areas that need refinement to improve the method's predictive power, but the results suggest that such approaches will provide a useful tool in cardiac safety assessment.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          hERG potassium channels and cardiac arrhythmia.

          hERG potassium channels are essential for normal electrical activity in the heart. Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias. Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs. This side effect is a common reason for drug failure in preclinical safety trials. Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A model for human ventricular tissue.

            The experimental and clinical possibilities for studying cardiac arrhythmias in human ventricular myocardium are very limited. Therefore, the use of alternative methods such as computer simulations is of great importance. In this article we introduce a mathematical model of the action potential of human ventricular cells that, while including a high level of electrophysiological detail, is computationally cost-effective enough to be applied in large-scale spatial simulations for the study of reentrant arrhythmias. The model is based on recent experimental data on most of the major ionic currents: the fast sodium, L-type calcium, transient outward, rapid and slow delayed rectifier, and inward rectifier currents. The model includes a basic calcium dynamics, allowing for the realistic modeling of calcium transients, calcium current inactivation, and the contraction staircase. We are able to reproduce human epicardial, endocardial, and M cell action potentials and show that differences can be explained by differences in the transient outward and slow delayed rectifier currents. Our model reproduces the experimentally observed data on action potential duration restitution, which is an important characteristic for reentrant arrhythmias. The conduction velocity restitution of our model is broader than in other models and agrees better with available data. Finally, we model the dynamics of spiral wave rotation in a two-dimensional sheet of human ventricular tissue and show that the spiral wave follows a complex meandering pattern and has a period of 265 ms. We conclude that the proposed model reproduces a variety of electrophysiological behaviors and provides a basis for studies of reentrant arrhythmias in human ventricular tissue.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Molecular determinants of cardiac transient outward potassium current (I(to)) expression and regulation.

              Rapidly activating and inactivating cardiac transient outward K(+) currents, I(to), are expressed in most mammalian cardiomyocytes, and contribute importantly to the early phase of action potential repolarization and to plateau potentials. The rapidly recovering (I(t)(o,f)) and slowly recovering (I(t)(o,s)) components are differentially expressed in the myocardium, contributing to regional heterogeneities in action potential waveforms. Consistent with the marked differences in biophysical properties, distinct pore-forming (alpha) subunits underlie the two I(t)(o) components: Kv4.3/Kv4.2 subunits encode I(t)(o,f), whereas Kv1.4 encodes I(t)(o,s), channels. It has also become increasingly clear that cardiac I(t)(o) channels function as components of macromolecular protein complexes, comprising (four) Kvalpha subunits and a variety of accessory subunits and regulatory proteins that influence channel expression, biophysical properties and interactions with the actin cytoskeleton, and contribute to the generation of normal cardiac rhythms. Derangements in the expression or the regulation of I(t)(o) channels in inherited or acquired cardiac diseases would be expected to increase the risk of potentially life-threatening cardiac arrhythmias. Indeed, a recently identified Brugada syndrome mutation in KCNE3 (MiRP2) has been suggested to result in increased I(t)(o,f) densities. Continued focus in this area seems certain to provide new and fundamentally important insights into the molecular determinants of functional I(t)(o) channels and into the molecular mechanisms involved in the dynamic regulation of I(t)(o) channel functioning in the normal and diseased myocardium. Copyright 2009 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Pharmacol Toxicol Methods
                J Pharmacol Toxicol Methods
                Journal of Pharmacological and Toxicological Methods
                Elsevier
                1056-8719
                1873-488X
                1 November 2014
                November 2014
                : 70
                : 3
                : 246-254
                Affiliations
                [a ]Computational Biology, Dept. of Computer Science, University of Oxford, Oxford OX1 3QD, UK
                [b ]Clinical Informatics, R&D Information, AstraZeneca, Alderley Park, SK10 4TG, UK
                [c ]Screening & Compound Profiling, GlaxoSmithKline, Stevenage SG1 2NY, UK
                [d ]Discovery Sciences, AstraZeneca, Alderley Park, SK10 4TG, UK
                [e ]Safety Evaluation and Risk Management, Global Clinical Safety, GlaxoSmithKline, Middlesex UB11 1BT, UK
                [f ]Translational Safety Department, Drug Safety & Metabolism, AstraZeneca, Alderley Park, SK10 4TG, UK
                Author notes
                [* ]Corresponding author. gary.mirams@ 123456cs.ox.ac.uk
                Article
                S1056-8719(14)00235-4
                10.1016/j.vascn.2014.07.002
                4266452
                25087753
                1933c9be-69e5-4024-96b2-7e0940443b7d
                © 2014 The Authors
                History
                Categories
                Original Article

                ap(d), action potential (duration),az, astrazeneca,b&q2, ionworks barracuda and second quattro screening dataset,glp, good laboratory practice,gsk, glaxosmithkline,ic50, concentration for 50% inhibition,ical, long-lasting-type calcium current,ikr, rapid delayed rectifier potassium current,iks, slow delayed rectifier potassium current,ina, fast sodium current,ito, transient outward potassium current,m&q, manual herg plus ionworks quattro screening dataset,pic50, minus log10 of ic50,q, ionworks quattro screening dataset,qt[c], qt interval of the electrocardiogram [corrected for heart rate],tqt, thorough qt (or ecg) study, a human clinical trial,high-throughput,compound screening,thorough qt,cardiac safety,methods,action potential,mathematical model

                Comments

                Comment on this article